Setting The Price for Remdesivir @Gilead Sciences – The first medicine shown to work against Covid-19, it does not save lives
Reporter: Aviva Lev-Ari, PhD, RN
UPDATED ON 6/29/2020
Gilead’s long-awaited remdesivir price is $3,120, in line with watchdog estimates
Will Gilead be able to make a profit out of remdeisivr at the current price? It looks like it.
At the $2,340 government purchase price, Gilead could collect revenue of about $2.3 billion from selling around 1.5 million remdeisivr treatment course in 2020, RBC Capital analyst Brian Abrahams wrote in a Monday note to clients. Gilead expects to spend about $1 billion developing and distributing remdesivir this year alone. That would imply around $1.3 billion in profit.
However, Abrahams figured there wouldn’t be much room for growth left afterward “given the likelihood of ultimate development of a vaccine (or herd immunity), the likelihood other therapies will produce similar or greater benefits perhaps with more convenient administration.”
Right now, Gilead’s planning to test an inhaled formulation of the drug for potential use in patients with earlier stages of the disease. It’s also exploring combinations with anti-inflammatory agents, including Roche’s Actemra and Eli Lilly’s Olumiant, both FDA-approved arthritis treatments.
During a Monday interview with CNBC’s “Squawk Box,” O’Day pointed to those second wave of clinical development investments as part of Gilead’s “dual responsibility” alongside access.
In the developing world, Gilead has penned nine deals with generic makers to offer remdesivir at low cost. For example, India’s Cipla and Hetero Labs have launched generic versions in their home country at around $70 per vial.
Remdesivir gets a price
After a long wait, Gilead Sciences has set a price for remdesivir, the first medicine shown to work against Covid-19. Now the debate over whether that price is fair can begin.
For all governments in the developed world, including the U.S. government’s Medicaid program and the Department of Veterans Affairs, Gilead will charge $2,340 for a five-day course. U.S. insurers will pay 33% more, or $3,120. Countries in the developing world will get the drug at greatly reduced prices through generic manufacturers to which Gilead has licensed production.
There has been speculation about the price for months, with the Institute for Clinical and Economic Review offering up arguments for a price anywhere between $10 and $5,080, and some Wall Street analysts making their own estimates.
“We spent a lot of time and considerable care and discussion about how to approach the pricing of this medicine,” Gilead CEO Daniel O’Day told STAT. “At this price it’s significantly below the value it brings to patients and to society. There is no doubt of that in my mind.”
SOURCE
From: STAT | The Readout <damian.garde@statnews.com>
Reply-To: STAT | The Readout <damian.garde@statnews.com>
Date: Monday, June 29, 2020 at 7:18 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Gilead announces remdesivir price, novel antibiotics get $1 billion, & patients die in gene therapy trial
Leave a Reply